Description
Description
Capsules are gelatinous, matte, yellow-beige, odorless, with a capsule Venoruton-yellow-yellow-300 contents color, odorless.
Release form
10 pcs. – blisters (5) – packs of cardboard.
Pharmacological action
The drug has an angioprotective and phlebotonizing effect. Derived routine. It acts mainly on capillaries and veins.
Reduces pores between endothelial cells by modifying the fibrous matrix located between endothelial cells. It inhibits aggregation and increases the degree of deformability of red blood cells.
Has anti-inflammatory effect.
In case of chronic venous insufficiency, Venoruton ® reduces the severity of such manifestations as edema, pain, cramps, trophic disorders, varicose ulcers. Reduces symptoms associated with hemorrhoids, including pain, itching, and bleeding.
Having a beneficial effect on the permeability and resistance of capillary walls, the drug slows the development of diabetic retinopathy.
Due to the effect of rutoside on the rheological properties of blood, the drug helps prevent retinal microtrombosis.
Indications
Chronic venous insufficiency postphlebitic syndrome
trophic disorders in varicose veins
trophic ulcers as an adjunct treatment for lymphostasis after sclerotherapy and removal of varicose veins
hemorrhoids, pain, starting from the second trimester
as an adjunct treatment of retinopathy in patients with diabetes mellitus, with arterial hypertension and atherosclerosis erose.
Contraindications
Hypersensitivity to rutosides or other components of the drug I trimester of pregnancy, children under 18 years of age.
Use with caution in liver, kidney, or heart failure.
Use during pregnancy and lactation
Clinical studies have examined the use of Venoruton in pregnancy, however, its use in the first trimester has not been specifically studied. Use in the first trimester of pregnancy is contraindicated.
In animal studies, no teratogenic and other adverse effects of the drug on the fetus were noted.
Prescribing Venoruton ® inside is recommended only starting from the second trimester of pregnancy, when the expected benefit for the mother from its use exceeds the possible risk to the fetus.
Special instructions
If the severity of the symptoms of the disease does not decrease with the use of the drug, it is recommended that the diagnosis be verified.
Composition
1 capsule contains:
Active ingredient:
hydroxyethylrutosides 300 mg,
Excipient:
macrogol 6000 – 9 mg
Empty hard gelatin capsule:
gelatin 0.2 mg – mg gelatin 0.25 mg about 1.5 mg dye iron oxide yellow – about 0.47 mg. Black ink is printed on the capsule, the capsule contains traces of
ink. The main ingredients of the ink for printing are:
shellac in ethanol, iron dye oxide black n-butanol propylene glycol isopropanol ammonia water.
Dosage and administration
Inside is prescribed at the beginning of treatment 300 mg (1 capsule) 3 times / day with meals. A decrease in the severity of symptoms is usually noted within 2 weeks of treatment.
It is recommended that the drug be continued in the same dose or reduced to a minimum maintenance dose of 600 mg / day, or treatment is stopped.
At the same time, the achieved effect lasts for 4 weeks.
Capsules are swallowed whole with plenty of water.
With lymphostasis, the recommended dose is 3 g / day.
In diabetic retinopathy, 0.9-1.8 g / day is prescribed.
Side effects
From the digestive system: nausea, diarrhea, heartburn.
Allergic reactions: skin rash.
Other: headache, flushing.
Side effects quickly disappear after discontinuation of the drug.
Drug Interactions
The effect of Venoruton is enhanced when used simultaneously with ascorbic acid.
Overdose
No cases of overdose that would be accompanied by clinical symptoms have been reported.
Storage conditions
The product should be stored in a dry place out of the reach of children at a temperature not exceeding 30 ° C.
Shelf life
3 years.
Terms and conditions
without prescription
dosage form
capsules
Prescribing
Prescribing
Adults, Pregnant II and III trimester as prescribed by the doctor
